Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Background: Inherited and sporadic medullary thyroid cancer (MTC) is an uncommon and challenging malignancy. The American Thyroid association (ATA) chose to create specific MTC Clinical Guidelines that would bring together and update the diverse MTC literature and combine it with evidence-based medi...
Gespeichert in:
Veröffentlicht in: | Thyroid (New York, N.Y.) N.Y.), 2009-06, Vol.19 (6), p.565-612 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 612 |
---|---|
container_issue | 6 |
container_start_page | 565 |
container_title | Thyroid (New York, N.Y.) |
container_volume | 19 |
creator | Kloos (Chair), Richard T. Eng, Charis Evans, Douglas B. Francis, Gary L. Gagel, Robert F. Gharib, Hossein Moley, Jeffrey F. Pacini, Furio Ringel, Matthew D. Schlumberger, Martin Wells, Samuel A. |
description | Background:
Inherited and sporadic medullary thyroid cancer (MTC) is an uncommon and challenging malignancy. The American Thyroid association (ATA) chose to create specific MTC Clinical Guidelines that would bring together and update the diverse MTC literature and combine it with evidence-based medicine and the knowledge and experience of a panel of expert clinicians.
Methods:
Relevant articles were identified using a systematic PubMed search and supplemented with additional published materials. Evidence-based recommendations were created and then categorized using criteria adapted from the United States Preventive Services Task Force, Agency for Healthcare Research and Quality.
Results:
Clinical topics addressed in this scholarly dialog included: initial diagnosis and therapy of preclinical disease (including
RET
oncogene testing and the timing of prophylactic thyroidectomy), initial diagnosis and therapy of clinically apparent disease (including preoperative testing and imaging, extent of surgery, and handling of devascularized parathyroid glands), initial evaluation and treatment of postoperative patients (including the role of completion thyroidectomy), management of persistent or recurrent MTC (including the role of tumor marker doubling times, and treatment of patients with distant metastases and hormonally active metastases), long-term follow-up and management (including the frequency of follow-up and imaging), and directions for future research.
Conclusions:
One hundred twenty-two evidence-based recommendations were created to assist in the clinical care of MTC patients and to share what we believe is current, rational, and optimal medical practice. |
doi_str_mv | 10.1089/thy.2008.0403 |
format | Article |
fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A202013911</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A202013911</galeid><sourcerecordid>A202013911</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-b8b2db64a63531010a98ee64b003151348d857803ab7159f824135d3fc0e86183</originalsourceid><addsrcrecordid>eNqFkMFLwzAUh4Mobk6PXqXgufWladLU2xg6hQ0PznNJ09ct0qYj6Q77723pUARB3uE9fny_d_gIuaUQUZDZQ7c7RjGAjCABdkamlPM0zCBNz_sbOIRpzMWEXHn_CUCFTNklmdAsEZnIYEre11ge6lq5Y7DZHV1rymChrEb3GKyVVVts0HbB8mBKrI1FH7RV0O0wmDfojFb2uzX3vtVGdaa11-SiUrXHm9OekY_np83iJVy9LV8X81WoEyG7sJBFXBYiUYJxRoGCyiSiSAoARjlliSwlTyUwVaSUZ5WME8p4ySoNKAWVbEbux79bVWNubNV2TunGeJ3PY4iBsozSnor-oPopsTG6tViZPv9VCMeCdq33Dqt870zTG8op5IPzvHeeD87zwXnP3438_lA0WP7QJ8k9wEZgiJW1tcECXffP2y8ey4uY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Kloos (Chair), Richard T. ; Eng, Charis ; Evans, Douglas B. ; Francis, Gary L. ; Gagel, Robert F. ; Gharib, Hossein ; Moley, Jeffrey F. ; Pacini, Furio ; Ringel, Matthew D. ; Schlumberger, Martin ; Wells, Samuel A.</creator><creatorcontrib>Kloos (Chair), Richard T. ; Eng, Charis ; Evans, Douglas B. ; Francis, Gary L. ; Gagel, Robert F. ; Gharib, Hossein ; Moley, Jeffrey F. ; Pacini, Furio ; Ringel, Matthew D. ; Schlumberger, Martin ; Wells, Samuel A. ; American Thyroid Association Guidelines Task Force</creatorcontrib><description>Background:
Inherited and sporadic medullary thyroid cancer (MTC) is an uncommon and challenging malignancy. The American Thyroid association (ATA) chose to create specific MTC Clinical Guidelines that would bring together and update the diverse MTC literature and combine it with evidence-based medicine and the knowledge and experience of a panel of expert clinicians.
Methods:
Relevant articles were identified using a systematic PubMed search and supplemented with additional published materials. Evidence-based recommendations were created and then categorized using criteria adapted from the United States Preventive Services Task Force, Agency for Healthcare Research and Quality.
Results:
Clinical topics addressed in this scholarly dialog included: initial diagnosis and therapy of preclinical disease (including
RET
oncogene testing and the timing of prophylactic thyroidectomy), initial diagnosis and therapy of clinically apparent disease (including preoperative testing and imaging, extent of surgery, and handling of devascularized parathyroid glands), initial evaluation and treatment of postoperative patients (including the role of completion thyroidectomy), management of persistent or recurrent MTC (including the role of tumor marker doubling times, and treatment of patients with distant metastases and hormonally active metastases), long-term follow-up and management (including the frequency of follow-up and imaging), and directions for future research.
Conclusions:
One hundred twenty-two evidence-based recommendations were created to assist in the clinical care of MTC patients and to share what we believe is current, rational, and optimal medical practice.</description><identifier>ISSN: 1050-7256</identifier><identifier>EISSN: 1557-9077</identifier><identifier>DOI: 10.1089/thy.2008.0403</identifier><identifier>PMID: 19469690</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Carcinoma, Medullary - diagnosis ; Carcinoma, Medullary - etiology ; Carcinoma, Medullary - therapy ; Care and treatment ; Evidence-based medicine ; Health aspects ; Humans ; Original Studies, Reviews, and Scholarly Dialog ; Practice guidelines (Medicine) ; Terminology as Topic ; Thyroid cancer ; Thyroid Neoplasms - diagnosis ; Thyroid Neoplasms - etiology ; Thyroid Neoplasms - therapy</subject><ispartof>Thyroid (New York, N.Y.), 2009-06, Vol.19 (6), p.565-612</ispartof><rights>2009, Mary Ann Liebert, Inc.</rights><rights>COPYRIGHT 2009 Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-b8b2db64a63531010a98ee64b003151348d857803ab7159f824135d3fc0e86183</citedby><cites>FETCH-LOGICAL-c468t-b8b2db64a63531010a98ee64b003151348d857803ab7159f824135d3fc0e86183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19469690$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kloos (Chair), Richard T.</creatorcontrib><creatorcontrib>Eng, Charis</creatorcontrib><creatorcontrib>Evans, Douglas B.</creatorcontrib><creatorcontrib>Francis, Gary L.</creatorcontrib><creatorcontrib>Gagel, Robert F.</creatorcontrib><creatorcontrib>Gharib, Hossein</creatorcontrib><creatorcontrib>Moley, Jeffrey F.</creatorcontrib><creatorcontrib>Pacini, Furio</creatorcontrib><creatorcontrib>Ringel, Matthew D.</creatorcontrib><creatorcontrib>Schlumberger, Martin</creatorcontrib><creatorcontrib>Wells, Samuel A.</creatorcontrib><creatorcontrib>American Thyroid Association Guidelines Task Force</creatorcontrib><title>Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association</title><title>Thyroid (New York, N.Y.)</title><addtitle>Thyroid</addtitle><description>Background:
Inherited and sporadic medullary thyroid cancer (MTC) is an uncommon and challenging malignancy. The American Thyroid association (ATA) chose to create specific MTC Clinical Guidelines that would bring together and update the diverse MTC literature and combine it with evidence-based medicine and the knowledge and experience of a panel of expert clinicians.
Methods:
Relevant articles were identified using a systematic PubMed search and supplemented with additional published materials. Evidence-based recommendations were created and then categorized using criteria adapted from the United States Preventive Services Task Force, Agency for Healthcare Research and Quality.
Results:
Clinical topics addressed in this scholarly dialog included: initial diagnosis and therapy of preclinical disease (including
RET
oncogene testing and the timing of prophylactic thyroidectomy), initial diagnosis and therapy of clinically apparent disease (including preoperative testing and imaging, extent of surgery, and handling of devascularized parathyroid glands), initial evaluation and treatment of postoperative patients (including the role of completion thyroidectomy), management of persistent or recurrent MTC (including the role of tumor marker doubling times, and treatment of patients with distant metastases and hormonally active metastases), long-term follow-up and management (including the frequency of follow-up and imaging), and directions for future research.
Conclusions:
One hundred twenty-two evidence-based recommendations were created to assist in the clinical care of MTC patients and to share what we believe is current, rational, and optimal medical practice.</description><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma, Medullary - diagnosis</subject><subject>Carcinoma, Medullary - etiology</subject><subject>Carcinoma, Medullary - therapy</subject><subject>Care and treatment</subject><subject>Evidence-based medicine</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Original Studies, Reviews, and Scholarly Dialog</subject><subject>Practice guidelines (Medicine)</subject><subject>Terminology as Topic</subject><subject>Thyroid cancer</subject><subject>Thyroid Neoplasms - diagnosis</subject><subject>Thyroid Neoplasms - etiology</subject><subject>Thyroid Neoplasms - therapy</subject><issn>1050-7256</issn><issn>1557-9077</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFLwzAUh4Mobk6PXqXgufWladLU2xg6hQ0PznNJ09ct0qYj6Q77723pUARB3uE9fny_d_gIuaUQUZDZQ7c7RjGAjCABdkamlPM0zCBNz_sbOIRpzMWEXHn_CUCFTNklmdAsEZnIYEre11ge6lq5Y7DZHV1rymChrEb3GKyVVVts0HbB8mBKrI1FH7RV0O0wmDfojFb2uzX3vtVGdaa11-SiUrXHm9OekY_np83iJVy9LV8X81WoEyG7sJBFXBYiUYJxRoGCyiSiSAoARjlliSwlTyUwVaSUZ5WME8p4ySoNKAWVbEbux79bVWNubNV2TunGeJ3PY4iBsozSnor-oPopsTG6tViZPv9VCMeCdq33Dqt870zTG8op5IPzvHeeD87zwXnP3438_lA0WP7QJ8k9wEZgiJW1tcECXffP2y8ey4uY</recordid><startdate>20090601</startdate><enddate>20090601</enddate><creator>Kloos (Chair), Richard T.</creator><creator>Eng, Charis</creator><creator>Evans, Douglas B.</creator><creator>Francis, Gary L.</creator><creator>Gagel, Robert F.</creator><creator>Gharib, Hossein</creator><creator>Moley, Jeffrey F.</creator><creator>Pacini, Furio</creator><creator>Ringel, Matthew D.</creator><creator>Schlumberger, Martin</creator><creator>Wells, Samuel A.</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20090601</creationdate><title>Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association</title><author>Kloos (Chair), Richard T. ; Eng, Charis ; Evans, Douglas B. ; Francis, Gary L. ; Gagel, Robert F. ; Gharib, Hossein ; Moley, Jeffrey F. ; Pacini, Furio ; Ringel, Matthew D. ; Schlumberger, Martin ; Wells, Samuel A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-b8b2db64a63531010a98ee64b003151348d857803ab7159f824135d3fc0e86183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma, Medullary - diagnosis</topic><topic>Carcinoma, Medullary - etiology</topic><topic>Carcinoma, Medullary - therapy</topic><topic>Care and treatment</topic><topic>Evidence-based medicine</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Original Studies, Reviews, and Scholarly Dialog</topic><topic>Practice guidelines (Medicine)</topic><topic>Terminology as Topic</topic><topic>Thyroid cancer</topic><topic>Thyroid Neoplasms - diagnosis</topic><topic>Thyroid Neoplasms - etiology</topic><topic>Thyroid Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kloos (Chair), Richard T.</creatorcontrib><creatorcontrib>Eng, Charis</creatorcontrib><creatorcontrib>Evans, Douglas B.</creatorcontrib><creatorcontrib>Francis, Gary L.</creatorcontrib><creatorcontrib>Gagel, Robert F.</creatorcontrib><creatorcontrib>Gharib, Hossein</creatorcontrib><creatorcontrib>Moley, Jeffrey F.</creatorcontrib><creatorcontrib>Pacini, Furio</creatorcontrib><creatorcontrib>Ringel, Matthew D.</creatorcontrib><creatorcontrib>Schlumberger, Martin</creatorcontrib><creatorcontrib>Wells, Samuel A.</creatorcontrib><creatorcontrib>American Thyroid Association Guidelines Task Force</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Thyroid (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kloos (Chair), Richard T.</au><au>Eng, Charis</au><au>Evans, Douglas B.</au><au>Francis, Gary L.</au><au>Gagel, Robert F.</au><au>Gharib, Hossein</au><au>Moley, Jeffrey F.</au><au>Pacini, Furio</au><au>Ringel, Matthew D.</au><au>Schlumberger, Martin</au><au>Wells, Samuel A.</au><aucorp>American Thyroid Association Guidelines Task Force</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association</atitle><jtitle>Thyroid (New York, N.Y.)</jtitle><addtitle>Thyroid</addtitle><date>2009-06-01</date><risdate>2009</risdate><volume>19</volume><issue>6</issue><spage>565</spage><epage>612</epage><pages>565-612</pages><issn>1050-7256</issn><eissn>1557-9077</eissn><abstract>Background:
Inherited and sporadic medullary thyroid cancer (MTC) is an uncommon and challenging malignancy. The American Thyroid association (ATA) chose to create specific MTC Clinical Guidelines that would bring together and update the diverse MTC literature and combine it with evidence-based medicine and the knowledge and experience of a panel of expert clinicians.
Methods:
Relevant articles were identified using a systematic PubMed search and supplemented with additional published materials. Evidence-based recommendations were created and then categorized using criteria adapted from the United States Preventive Services Task Force, Agency for Healthcare Research and Quality.
Results:
Clinical topics addressed in this scholarly dialog included: initial diagnosis and therapy of preclinical disease (including
RET
oncogene testing and the timing of prophylactic thyroidectomy), initial diagnosis and therapy of clinically apparent disease (including preoperative testing and imaging, extent of surgery, and handling of devascularized parathyroid glands), initial evaluation and treatment of postoperative patients (including the role of completion thyroidectomy), management of persistent or recurrent MTC (including the role of tumor marker doubling times, and treatment of patients with distant metastases and hormonally active metastases), long-term follow-up and management (including the frequency of follow-up and imaging), and directions for future research.
Conclusions:
One hundred twenty-two evidence-based recommendations were created to assist in the clinical care of MTC patients and to share what we believe is current, rational, and optimal medical practice.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>19469690</pmid><doi>10.1089/thy.2008.0403</doi><tpages>48</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1050-7256 |
ispartof | Thyroid (New York, N.Y.), 2009-06, Vol.19 (6), p.565-612 |
issn | 1050-7256 1557-9077 |
language | eng |
recordid | cdi_gale_infotracmisc_A202013911 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Medullary - diagnosis Carcinoma, Medullary - etiology Carcinoma, Medullary - therapy Care and treatment Evidence-based medicine Health aspects Humans Original Studies, Reviews, and Scholarly Dialog Practice guidelines (Medicine) Terminology as Topic Thyroid cancer Thyroid Neoplasms - diagnosis Thyroid Neoplasms - etiology Thyroid Neoplasms - therapy |
title | Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T14%3A57%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medullary%20Thyroid%20Cancer:%20Management%20Guidelines%20of%20the%20American%20Thyroid%20Association&rft.jtitle=Thyroid%20(New%20York,%20N.Y.)&rft.au=Kloos%20(Chair),%20Richard%20T.&rft.aucorp=American%20Thyroid%20Association%20Guidelines%20Task%20Force&rft.date=2009-06-01&rft.volume=19&rft.issue=6&rft.spage=565&rft.epage=612&rft.pages=565-612&rft.issn=1050-7256&rft.eissn=1557-9077&rft_id=info:doi/10.1089/thy.2008.0403&rft_dat=%3Cgale_cross%3EA202013911%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19469690&rft_galeid=A202013911&rfr_iscdi=true |